The T120P or M172V mutation on rv2172c confers high level para -aminosalicylic acid resistance in Mycobacterium tuberculosis
Open Access
- 24 July 2024
- journal article
- research article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2374030
Abstract
Although para-aminosalicylic acid (PAS) has been used to treat tuberculosis for decades, mechanisms of resistance to this drug in Mycobacterium tuberculosis (M. tuberculosis) clinical isolates have not been thoroughly investigated. Previously, we found that decreased methylenetetrahydrofolate reductase (MTHFR) activity of Rv2172c led to increased sensitivity to antifolates in M. tuberculosis. In this study, we collected the genome-sequencing data of 173 PAS-resistant and 803 PAS-sensitive clinical isolates and analyzed rv2172c mutations in those 976 isolates. The results showed that two mutations (T120P and M172V) on rv2172c could be identified in a certain proportion (6.36%) of PAS-resistant isolates. The results of AlphaFold2 prediction indicated that the T120P or M172V mutation might affect the enzymatic activity of Rv2172c by influencing nicotinamide adenine dinucleotide (NADH) binding, and this was verified by subsequent biochemical analysis, demonstrating the role of residues Thr120 and Met172 on NADH binding and enzymatic activity of Rv2172c. In addition, the effect of rv2172c T120P or M172V mutation on methionine production and PAS resistance was determined in M. tuberculosis. The results showed that both T120P and M172V mutations caused increased intracellular methionine concentrations and high level PAS resistance. In summary, we discovered new molecular markers and also a novel mechanism of PAS resistance in M. tuberculosis clinical isolates and broadened the understanding of the NADH-dependent MTHFR catalytic mechanism of Rv2172c in M. tuberculosis, which will facilitate the molecular diagnosis of PAS resistance and also the development of new drugs targeting Rv2172c.Keywords
Funding Information
- Ministry of Science and Technology of the People’s Republic of China (2021YFA1300901)
This publication has 45 references indexed in Scilit:
- The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosisThe Lancet Respiratory Medicine, 2023
- Biochemical and structural characterization of meningococcal methylenetetrahydrofolate reductaseProtein Science, 2023
- Assessment of the 2021 WHO Mycobacterium tuberculosis drug resistance mutation catalogue on an independent datasetThe Lancet Microbe, 2022
- Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting AgentsCell Chemical Biology, 2019
- Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid ResistanceBiochemistry, 2016
- Structural Perturbations in the Ala → Val Polymorphism of Methylenetetrahydrofolate Reductase: How Binding of Folates May Protect against Inactivation,Biochemistry, 2006
- Structures of NADH and CH3-H4Folate Complexes of Escherichia coli Methylenetetrahydrofolate Reductase Reveal a Spartan Strategy for a Ping-Pong Reaction,Biochemistry, 2005
- Methylenetetrahydrofolate reductase and methionine synthase: biochemistry and molecular biologyEuropean Journal of Pediatrics, 1998
- Comparison of cobalamin-independent and cobalamin-dependent methionine synthases from Escherichia coli: two solutions to the same chemical problemBiochemistry, 1992
- PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSISThe Lancet, 1946